BLAINJECTIONINJECTABLE
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
TRAZIMERA (trastuzumab-qyyp) by Pfizer is her2/neu/cerbb2 antagonists [moa]. Approved for her2/neu receptor antagonist [epc]. First approved in 2019.
Drug data last refreshed 6h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRAZIMERA (trastuzumab-qyyp) is a Pfizer-sponsored monoclonal antibody biosimilar targeting HER2/neu receptors, indicated for HER2-positive breast cancer and gastric cancer. It works by binding to HER2 receptors on cancer cells, blocking growth signaling and inducing immune-mediated cell death. As a biosimilar to reference trastuzumab (Herceptin), it offers comparable efficacy at potentially lower cost.
$5MPart D
PeakStable
TRAZIMERA is in peak lifecycle with modest Part D penetration ($5M spending, 1,147 claims in 2023), suggesting a growing but not yet dominant position within the crowded HER2-antagonist biosimilar market.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRAZIMERA positions you in a mature biosimilar franchise with significant competitive pressure and commoditized economics, requiring expertise in payer negotiation, formulary management, and cost-based selling rather than innovative clinical differentiation. Career growth depends on success in market access and competitive positioning; limited clinical development opportunities mean advancement may require cross-functional or portfolio-level progression within Pfizer's oncology unit.
Brand Manager
Worked on TRAZIMERA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.